Tokyo Tape
Sign in
← Alfresa Holdings

Quarterly report · Q1

2784.TEDINET S100RN02
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥709.1bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥2.70T2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥657.1bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥5.8bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥3.1bn2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥6.4bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥32.8bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.7bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥6.4bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥3.6bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥4.0bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥25.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥4.1bn2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥2.2bn2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥1.39Tat 2023-06-30Cons.Assets
Total assets¥1.34Tat 2023-03-31Cons.Assets
Total assets¥1.33Tat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥909.2bnat 2023-06-30Cons.Liabilities
Total liabilities¥851.5bnat 2023-03-31Cons.Liabilities
Net assets / equity¥479.9bnat 2023-06-30Cons.Net assets
Net assets / equity¥488.3bnat 2023-03-31Cons.Net assets
Net assets / equity¥475.5bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥169.4bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥160.1bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥20.152023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥127.422022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥10.52022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio34.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.4%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio35.8%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥8.4bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥8.4bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30¥129m
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥631.6bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥626.8bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥4.8bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥5.3bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥12.3bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥8.8bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥3.5bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentsegment profit2023-04-01 → 2023-06-30−¥442m
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥8.9bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥8.9bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥82m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥64.6bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥64.5bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥153m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥770m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥717.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥709.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥8.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥5.7bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥7.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥7.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30¥82m
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥585.4bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥580.9bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.4bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥11.0bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.9bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.1bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥207m
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentsegment profit2022-04-01 → 2022-06-30−¥92m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥59.6bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥59.5bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥142m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥448m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥664.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥657.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥7.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥3.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 371
ItemContextValueUnit
Short term loans payableCurrentQuarterInstant2500000000JPY
Income taxes payablePrior1YearInstant6046000000JPY
Income taxes payableCurrentQuarterInstant6283000000JPY
Provision for bonusesPrior1YearInstant7210000000JPY
Provision for bonusesCurrentQuarterInstant8373000000JPY
Provision for directors bonusesPrior1YearInstant384000000JPY
Provision for directors bonusesCurrentQuarterInstant142000000JPY
Provision for loss on anti monopoly act cl provisionsPrior1YearInstant4937000000JPY
Provision for loss on anti monopoly act cl provisionsCurrentQuarterInstant4937000000JPY
Other clPrior1YearInstant26810000000JPY
Other clCurrentQuarterInstant30218000000JPY
Current liabilitiesPrior1YearInstant825732000000JPY
Current liabilitiesCurrentQuarterInstant881510000000JPY
Provision for share based remuneration nclPrior1YearInstant73000000JPY
Provision for share based remuneration nclCurrentQuarterInstant111000000JPY
Provision for share based remuneration for directors and other officers nclPrior1YearInstant90000000JPY
Provision for share based remuneration for directors and other officers nclCurrentQuarterInstant135000000JPY
Net defined benefit liabilityPrior1YearInstant8363000000JPY
Net defined benefit liabilityCurrentQuarterInstant8822000000JPY
Other nclPrior1YearInstant17257000000JPY
Other nclCurrentQuarterInstant18635000000JPY
Noncurrent liabilitiesPrior1YearInstant25784000000JPY
Noncurrent liabilitiesCurrentQuarterInstant27704000000JPY
LiabilitiesPrior1YearInstant851517000000JPY
LiabilitiesCurrentQuarterInstant909214000000JPY
Capital stockPrior1YearInstant18454000000JPY
Capital stockCurrentQuarterInstant18454000000JPY
Capital surplusPrior1YearInstant57720000000JPY
Capital surplusCurrentQuarterInstant57720000000JPY
Retained earningsPrior1YearInstant366649000000JPY
Retained earningsCurrentQuarterInstant365341000000JPY
Treasury stockPrior1YearInstant-686000000JPY
Treasury stockCurrentQuarterInstant-13444000000JPY
Shareholders equityPrior1YearInstant442137000000JPY
Shareholders equityCurrentQuarterInstant428071000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant47135000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant52873000000JPY
Deferred gains or losses on hedgesPrior1YearInstant-0JPY
Deferred gains or losses on hedgesCurrentQuarterInstant0JPY
Revaluation reserve for landPrior1YearInstant-3346000000JPY
Revaluation reserve for landCurrentQuarterInstant-3346000000JPY
Foreign currency translation adjustmentPrior1YearInstant269000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant286000000JPY
Remeasurements of defined benefit plansPrior1YearInstant1895000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant1775000000JPY
Valuation and translation adjustmentsPrior1YearInstant45953000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant51589000000JPY
Non controlling interestsPrior1YearInstant244000000JPY
Non controlling interestsCurrentQuarterInstant264000000JPY
Net assetsPrior1YearInstant488335000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass